Theseus Pharmaceuticals, Inc.
Theseus Pharmaceuticals, Inc. (THRX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
thrx · stock forecast · 12 analysts (3M) · FMP · updated Oct 11, 2024
Analyst Rating & Consensus
Based on 12 Wall Street analysts in the past 3 months
Buy
12 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $4.06
Short-Term Price Prediction
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · THRX · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-07-14 | Needham | Downgrade ↓ | Buy→Hold |
| 2023-07-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-07-14 | Wedbush | Maintains | Outperform→Outperform |
| 2023-07-14 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2023-07-13 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-07-13 | Needham | Downgrade ↓ | Buy→Hold |
| 2023-07-13 | Wedbush | Maintains | Outperform→Outperform |
| 2023-07-13 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2023-05-26 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-05-26 | Needham | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Theseus Pharmaceuticals, Inc. (THRX) stock. Of the recent 40 rating actions, 1 were upgrades and 6 were downgrades. 12 analysts currently cover THRX.
Analyst Recommendation Trends
THRX analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 6 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
Revenue Next Year
$0M
EPS This Year
$-1.32
EPS Next Year
$-1.43
↑ 8.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast THRX EPS of $-1.32 for the current fiscal year, based on estimates from 2 analysts. The THRX revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The THRX stock forecast is supported by two independent data sources: analyst consensus ratings from 12 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus THRX price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
Theseus Pharmaceuticals, Inc. trades on NASDAQ under the ticker THRX. The THRX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 67% of covering analysts.
Frequently asked questions
THRX forecast · 8 questionsAccording to 12 Wall Street analysts, the average 12-month THRX price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $4.06.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.